Pathogenic Variants as Biomarkers for Risk in Prostate Cancer.

Studies have demonstrated that men with Prostate Cancer (PCa) harboring genetic aberrations, are more likely to have worse disease and a poorer prognosis. A mutation in is known to confer the highest risk of PCa for men (8.6 fold in men ≤65 years) making genes a conceivable genomic biomarker for risk in PCa. These genes have attracted a lot of research attention however their role in the clinical assessment and treatment of PCa remains complex. Multiple studies have been published examining the relationship between prostate cancer and mutations. Here mutations are explored specifically as a biomarker for risk in PCa. It is in this context, we examined the prognostic, clinical and therapeutic role of mutations across the evolution of PCa. The impact of the inclusion of genes on genetic screening will also be outlined.